Literature DB >> 11001111

Doxycycline use for rickettsial disease in pediatric patients.

J J Purvis1, M S Edwards.   

Abstract

BACKGROUND: Recent evidence suggests that despite potential side effects, doxycycline should be considered the drug of choice for children of all ages in whom a rickettsial disease is considered in the differential diagnosis of the illness. We hypothesized that doxycycline would be used infrequently for the treatment of suspected rickettsial disease. The objective of the investigation was to determine the initial antibiotic administered to children for whom rickettsial infection was considered likely.
METHODS: The study population consisted of 35 children evaluated at Texas Children's Hospital between 1987 and 1999 in whom rickettsial disease was a diagnostic consideration. Demographic information and clinical manifestations were assessed through a retrospective chart review.
RESULTS: Thirty children (86%) presented with fever, 21 (60%) with rash and 14 (40%) with headache, which are typical presenting symptoms for rickettsial diseases. Only 1 of 35 children (3%) was prescribed a tetracycline class antibiotic as initial empiric therapy. Eleven (31%) children received doxycycline during the hospital course. A total of 19 patients, or 54%, received an antimicrobial known to have efficacy in the treatment of rickettsial infection, usually at the suggestion of an infectious diseases consultant.
CONCLUSIONS: Even among children for whom rickettsial infection is a diagnostic consideration, doxycycline is not prescribed with the frequency that is indicated. Pediatric caregivers should have heightened awareness regarding the appropriate indications for doxycycline use in childhood.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11001111     DOI: 10.1097/00006454-200009000-00011

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  11 in total

1.  Dermatologic Infectious Diseases in International Travelers.

Authors:  Mary E. Wilson; Lin H. Chen
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

2.  Analysis of fluorescent protein expression in transformants of Rickettsia monacensis, an obligate intracellular tick symbiont.

Authors:  Gerald D Baldridge; Nicole Burkhardt; Michael J Herron; Timothy J Kurtti; Ulrike G Munderloh
Journal:  Appl Environ Microbiol       Date:  2005-04       Impact factor: 4.792

3.  Knowledge, attitudes, and practices regarding Rocky Mountain spotted fever among healthcare providers, Tennessee, 2009.

Authors:  Emily Mosites; L Rand Carpenter; Kristina McElroy; Mary J Lancaster; Tue H Ngo; Jennifer McQuiston; Caleb Wiedeman; John R Dunn
Journal:  Am J Trop Med Hyg       Date:  2012-12-12       Impact factor: 2.345

4.  In vitro and in vivo antimalarial efficacies of optimized tetracyclines.

Authors:  Michael P Draper; Beena Bhatia; Haregewein Assefa; Laura Honeyman; Lynne K Garrity-Ryan; Atul K Verma; Jiri Gut; Kelley Larson; Janice Donatelli; Ann Macone; Kevin Klausner; Raina G Leahy; Aleksandrs Odinecs; Kwasi Ohemeng; Philip J Rosenthal; Mark L Nelson
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

5.  Fatal Rocky Mountain spotted fever in the United States, 1999-2007.

Authors:  F Scott Dahlgren; Robert C Holman; Christopher D Paddock; Laura S Callinan; Jennifer H McQuiston
Journal:  Am J Trop Med Hyg       Date:  2012-04       Impact factor: 2.345

Review 6.  Tick-borne rickettsioses around the world: emerging diseases challenging old concepts.

Authors:  Philippe Parola; Christopher D Paddock; Didier Raoult
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

7.  Rickettsial illnesses, a leading cause of acute febrile illness.

Authors:  Ranjan Premaratna
Journal:  Clin Med (Lond)       Date:  2022-01       Impact factor: 2.659

8.  Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis.

Authors:  Kathrine R Tan; Alan J Magill; Monica E Parise; Paul M Arguin
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

Review 9.  Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?

Authors:  Ruby Cross; Clare Ling; Nicholas P J Day; Rose McGready; Daniel H Paris
Journal:  Expert Opin Drug Saf       Date:  2016-01-25       Impact factor: 4.250

10.  Multiple Ehrlichia chaffeensis Genes Critical for Its Persistent Infection in a Vertebrate Host Are Identified by Random Mutagenesis Coupled with In Vivo Infection Assessment.

Authors:  Ying Wang; Arathy D S Nair; Andy Alhassan; Deborah C Jaworski; Huitao Liu; Kathleen Trinkl; Paidashe Hove; Charan K Ganta; Nicole Burkhardt; Ulrike G Munderloh; Roman R Ganta
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.